ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jeff I agree, though female testosterone will likely become a franchise blockbuster with many indications. Corti is what the public is currently seeing, and it has the potential to be a blockbuster, as well. Corti was previously approved for many indications. Even with label matching for all the indications, in order to gain acceptance by physicians for all the indications, more studies will be required.

Hard to tell what PPS will be, as institutions are currently depressing PPS. We are looking at Novitium deal closing and a revenue guidance increase to approximately $300 million, before Corti gets approved. Price should move up considerably before Corti gets approved, if the institutions let it run.

ANIP was trading in the $80 when they had consistent quarter over quarter growth. This was before Corti was close to being filed. If they can get that trend going again, it too, will bring in investors.

GuruFocus put Fair Value for ANIP today at $60.06 PPS. Once the Novitium deal closes, fair value with new guidance will likely be between $70 and $75 (50% increase in revenue, offset by approximately 20% increase in outstanding shares). Assuming $300 million in revenue for Corti is projected. One could argue fair value will be somewhere between $140 and $150 PPS. PPS should approach $200 if the can generate $300 million in Corti Revenue.

If the institutions let her run, PPS should surpass Fair value as the Market cap increase will lead to additional buyers, particularly since ANIP moves into Mid cap territory, bringing in additional institutional investors.

JMHO